IRRAS is a privately-held commercial medical device company that develops and commercializes innovative solutions that are designed to transform neurocritical care. Our initial clinical focus is on neurosurgical procedures, where excess cerebrospinal fluid (CSF) or toxic blood byproducts often need to be emergently drained and intracranial pressure (ICP) needs to be closely regulated.
IRRAS’ first commercial product, IRRAflow®, is a next-generation intracranial fluid management system that consists of a patented dual lumen catheter, intelligent cassette, and control unit with proprietary software that work together to manage the drainage of excess fluid, intelligently regulate the patient’s ICP, and, on a regular basis, proactively flush the catheter to enable active fluid exchange.
These catheter blockages occur more than 40% of the time1 with legacy passive drainage systems and can result in inefficient drainage and excessively high infection rates.2 IRRAflow’s combination of recurring irrigation, controlled drainage, and continuous patient monitoring active addresses these shortcomings and provides a new standard of care for how patients in the neurosurgical intensive care unit are managed.
Through continued technological advances, IRRAS remains focused on developing innovative features for IRRAflow as well as new products and applications based on our core fluid exchange technologies. In the future, we envision new therapeutic applications for the IRRAflow platform, including targeted drug delivery and drainage in other clinical areas.
IRRAS is headquartered in San Diego, California
